Search

These projects investigate disease progression and novel therapeutics for two muscle disease: rhabdomyosarcoma and nemaline myopathy.

We are using mainly PSMA as a target to image prostate cancer. PSMA is a dimeric type II integral membrane glycoprotein, highly expressed on prostate cancer cells but also on tumor neovasculature. Our lab is interested in PSMA (i) as a target for prostate cancer imaging and therapy usingtheranostic particles and activatable imaging agents, and (ii) in the biological function of PSMA and its role in neovascularization. We are also exploring ways to image sentinel nodes in prostate (and ultimately other) cancers.